- Hazard ratio for in-hospital mortality amongst hospitalized patients in New York City were not significantly different for those given Azithromycin

- Odds of cardiac arrest were not higher amongst patients given Azithromycin compared to those who got Hydrochloroquine, Azithromycin+Hydrochloroquine, or neither drug. 

- Patients who received Azithromycin did not have higher odds of abnormal ECG findings compared to those who got Hydrochloroquine, Azithromycin+Hydrochloroquine, or neither drug. 

Findings about use of Azithromycin as COVID-19 intervention from study of hospitalized patients in New York City

University of Michigan - Ann Arbor

Azithromycin (AZM) appears to have no significant effect on COVID-19 outcomes, but its use does not increase the risk of other negative health outcomes in patients.

Azithromycin (AZM) as treatment for COVID-19

Findings opposed to Azithromycin (AZM) as treatment for COVID-19

- CD147 acts as a receptor for Plasmodium falciparum invasion on red blood cells and as a receptor on host cells for SARS-CoV-2 infection  
- AZM triggers anti-viral responses in epithelial cells by increasing interferon and interferon-stimulated protein levels and decreasing viral replication and viral release 
- AZM decreases expression of metalloproteinases, which are closely related to CD147
- Influenza A virus in cells of Asthma patients and high glucose concentrations have shown to lead to increased CD147 expression, which suggests correlations within asthma, diabetes, and CD147 levels due to clinical complications of COVID-19 


Learn Before

Related

Learn After